Shinichi Takahashi

Jan 16, 2025 | jnnp.bmj.com | Chris Kato |Satoru Morimoto |Shinichi Takahashi |Shinichi Namba

Spinal cord motor neuron phenotypes and polygenic risk scores in sporadic amyotrophic lateral sclerosis: deciphering the disease pathology and therapeutic potential of ropinirole hydrochloride Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.

Sep 3, 2024 | jnnp.bmj.com | Chris Kato |Satoru Morimoto |Shinichi Takahashi |Shinichi Namba

X @NambaShinichiContributors CK, SM and ST designed the study and acquired samples from patients. CK analysed the data and performed statistical analyses. CK, SM, ST, SN, QW, YO and HO contributed to the interpretation of the results. ST, SN, QW, YO and HO provided supervision. CK and SM wrote the manuscript, and all authors corrected the manuscript and collectively made the decision to submit for publication.

Mar 7, 2024 | medrxiv.org | Chris Kato |Satoru Morimoto |Shinichi Takahashi |Shinichi Namba

Hideyuki Okano reports grants and personal fees as a Chief Scientific Officer from K Pharma, Inc. during the conduct of the study; personal fees from Sanbio Co. Ltd., outside the submitted work; In addition, Hideyuki Okano has a patent on a therapeutic agent for amyotrophic lateral sclerosis and composition for treatment licensed to K Pharma, Inc. Q.S.W is currently an employee of Calico Life Science LLC. Involvement in the presented research was prior to the affiliation.